Skip to content

Thermal ablation of thyroid papillary microcarcinoma (Radio Frequency, Microwave and Laser) of clinical multi-center study

Thermal ablation of thyroid papillary microcarcinoma (Radio Frequency, Microwave and Laser) of clinical multi-center study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONN-16008479
Enrollment
Unknown
Registered
2016-05-16
Start date
2016-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid papillary microcarcinoma

Interventions

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: The patients who selected should be confirmed by two of ultrsonic associate professor or professorthe and one of associate professor or professorthe of surgery, and meet all of the following conditions: 1) Ultrasound find single suspicious malignant nodules, 1 cm or less in diameter, not close to the capsule (2 mm or higher), FNA confirmed (checked by at least one pathological associate professor or professorthe ) of papillary carcinoma, neck without suspicious lymph node metastasis; 2) After the assessment, the patient's condition cannot tolerate surgery or refused surgical treatment; 3) patients feel pressure about tumor and refuses to clinical observation (patients with minimally invasive interventional therapy).

Exclusion criteria

Exclusion criteria: Comply with any of the following article is ruled out: 1) confirmed by FNA that it is multifocal papillary thyroid microcarcinoma; 2) bulky calcifications in PTMC; 3) suspicious metastatic lymph nodes were founded; 4) patients with a family history of thyroid cancer or (and) radiotherapy history and other risk factors; 5) contralateral vocal cord function abnormal; 6) serious coagulation disorders; 7) Severe lung or(and) heart disease; 8) Refused to sign the informed consent.

Design outcomes

Primary

MeasureTime frame
conventional ultrasound;contrast-enhance ultrasound;head and neck CT;ECT;laryngoscope;chest radiography;ECG;cardiac sonography;thyroid gland function;thyroid autoimmune antibody;serum calcium;Hepatic function;coagulative function index;FNAB;

Countries

China

Contacts

Public ContactMinghua Ge

Zhejiang Cancer Hospital

gemh@zjcc.org.cn+86 13605813782

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026